Does 280E Apply to a GLP-1 Compounding Pharmacy? A Statutory Read

Some operators and their advisors have asked whether the controlled handling of GLP-1 prescriptions, the FDA shortage rules, or the DEA Form 222 culture in adjacent pharmacy operations creates any 280E exposure for a compounding pharmacy. The short answer is no. The longer answer matters because it shapes how a compounding operator structures its books, picks an entity, and forecasts the next eighteen months of revenue.

We maintain that the analysis here is straightforward when you read the statute rather than the trade-press summaries. 280E is a narrow rule with specific triggers, and a GLP-1 compounding operation does not pull any of them.

What 280E Actually Requires

IRC 280E disallows any deduction or credit for amounts paid or incurred in a trade or business that consists of trafficking in controlled substances within the meaning of Schedule I or II of the Controlled Substances Act. Relying on the statutory language, two elements must be present before 280E is triggered: trafficking, and a Schedule I or II substance.

Semaglutide is not a scheduled controlled substance. Tirzepatide is not a scheduled controlled substance. GLP-1 receptor agonists as a therapeutic class are not scheduled. They are prescription drugs regulated by FDA under the Food, Drug, and Cosmetic Act, not by DEA under the CSA.

That ends the 280E inquiry. A compounding pharmacy handling semaglutide or tirzepatide is a normal trade or business for federal income tax purposes. Full IRC 162 deductibility applies to ordinary and necessary business expenses. Rent, wages, marketing, professional fees, software, insurance, and overhead are all deductible without the disallowance the IRS continues to assert against cannabis operators - an application we have publicly challenged.

503A vs 503B - A Tax Lens

The federal tax posture of a compounding pharmacy depends heavily on which section of the FDCA the operator practices under. The two structures look similar from the outside and diverge sharply once you open the general ledger.

• 503A - patient-specific compounding by a licensed pharmacist against a valid prescription for an individually identified patient. Smaller scale, lower CapEx, often organized as a PA, PC, or PLLC with an S-corp election. Pharmacist owner takes reasonable compensation on W-2 and the residual flows through.
• 503B - FDA-registered outsourcing facility producing in bulk for distribution to hospitals, clinics, and provider offices. Higher CapEx on clean rooms, ISO-classified suites, isolators, autoclaves, and HVAC. Often a candidate for C-corp structure when there is institutional capital, growth reinvestment, or a multi-state distribution footprint.

Inventory accounting under IRC 471 applies to both. API powders, excipients, vials, stoppers, and work-in-process are inventory and need to be tracked, valued, and tied to cost of goods sold by SKU. Small-taxpayer relief under IRC 471(c) is available for qualifying operators, but larger 503B facilities and growing 503A pharmacies can exceed the gross receipts threshold and must follow full inventory rules.

503B operators typically benefit from a disciplined accelerated depreciation strategy. A cost segregation study on a build-out that includes clean rooms, process piping, specialized electrical, and compounding equipment will reclassify a meaningful share of the project from 39-year real property into 5-, 7-, and 15-year asset lives, with the corresponding bonus depreciation treatment available under current law.

The Post-Shortage Compounding Window Is Mostly Closed

The commercial reality of GLP-1 compounding changed materially in late 2024 and early 2025, and the tax planning needs to catch up.

• FDA removed tirzepatide from the shortage list in October 2024 and confirmed that determination in December 2024 after reconsideration.
• FDA declared the semaglutide shortage resolved in February 2025.

Once a shortage is resolved, the broad permission to compound a commercial-equivalent copy of the FDA-approved drug ends. Section 503A compounding of semaglutide and tirzepatide is now permitted only on a documented clinical-difference basis, such as a documented allergy to an inactive ingredient in the commercial product or a dose strength that is not commercially available for the patient. 503B compounding remains permitted under narrower criteria tied to the outsourcing facility framework.

The tax planning implication is direct. Operators who built revenue on commercial-equivalent GLP-1 compounding during the shortage need to forecast a revenue mix shift, not a flat continuation. That shift touches several lines of the return:

• Depreciation schedules built on a peak-revenue assumption may need revisiting, particularly where bonus depreciation was layered on equipment that will run below capacity.
• Entity structure decisions made during a high-margin window may not survive a normalized margin profile. An S-corp election made on a 35-percent-margin business reads differently at 15 percent.
• Reasonable compensation for pharmacist owners needs to be re-benchmarked against the new revenue base, not the shortage-era base.
• State apportionment and nexus footprints built around mail-order cash-pay programs may need to be redrawn.

Where the Real Risk Lives (Not 280E)

The risk register for a GLP-1 compounding operator is real. It just is not a 280E register. We maintain that the operators getting hurt in this space are getting hurt on the regulatory and structural side, not the federal income tax side.

• FDA enforcement risk on compounding outside the clinical-difference window now that both shortages are resolved. Warning letters and 483 observations carry both direct cost and downstream commercial fallout.
• State pharmacy board inspection findings, which can suspend licensure and freeze revenue overnight regardless of how the federal return is structured.
• Sales tax exposure on cash-pay programs in states that treat compounded prescription drugs as taxable, or that treat the transaction as taxable when it is not dispensed against a third-party payor claim.
• Payment processor risk. Payment-processor policies for pharmacies, telehealth, and peptide-related products vary and can change without much notice. A frozen merchant account is a cash flow event, not a tax event, but it ends businesses.
• Product liability exposure, which drives entity choice, insurance limits, and the case for separating the licensed pharmacy entity from the holding company and from any owned real estate.

Practical Tax Hygiene for a Compounding Operator

The hygiene items below are the ones we put in front of every compounding client at intake. None of them are exotic. All of them get missed.

1. Separate the licensed pharmacy operating entity from the holding company, and separate real estate from both. Three entities, three sets of books, three bank accounts.
2. Run real payroll for the pharmacist owner. Avoid the S-corp distribution and W-2 imbalance trap that the IRS targets in professional service businesses. Reasonable compensation is a documentation exercise, not a guess.
3. Maintain GAAP-aligned monthly books with COGS tracked by SKU. Inventory under IRC 471 is not optional once you cross the small-taxpayer threshold, and SKU-level COGS is how you defend gross margin in an audit or in a financing process.
4. File and pay state sales tax in every nexus state where the transaction is taxable for cash-pay product. Economic nexus thresholds catch mail-order pharmacies faster than most operators expect.
5. Engage a CPA familiar with both IRC 471(c) inventory accounting and FDA-regulated industry compliance. The combination is what protects margin and survives diligence.

280E is not a compounding pharmacy concern. The statute does not reach this fact pattern, and no amount of adjacent pharmacy folklore changes that. The real concerns are FDA enforcement, state pharmacy board oversight, payment processor stability, and entity structure. Calyx CPA prepares returns and structures entities for both 503A patient-specific pharmacies and 503B outsourcing facilities, and we are happy to read your operating documents against your tax posture before the next filing cycle.

This article is intended for informational purposes only and does not constitute legal, tax, or medical advice.